Cystatin C GFR (CKD-EPI CysC 2012)
Biological Sex
Részletes útmutató hamarosan
Dolgozunk egy átfogó oktatási útmutatón a(z) Cystatin C eGFR Calculator számára. Nézzen vissza hamarosan a lépésről lépésre történő magyarázatokért, képletekért, valós példákért és szakértői tippekért.
Cystatin C GFR estimation uses serum cystatin C — a small protein produced at a constant rate by all nucleated cells and freely filtered, then fully reabsorbed and catabolised by the renal tubules — as an endogenous filtration marker to estimate glomerular filtration rate. Unlike serum creatinine, cystatin C production is not significantly influenced by muscle mass, age-related changes in muscle composition, sex, or dietary protein intake. This makes it a superior GFR marker in populations where creatinine performs poorly: sarcopenic elderly, amputees, patients with muscle-wasting diseases, malnourished patients, obese patients, and those on high-protein or vegan diets. The 2012 CKD-EPI Cystatin C equation (developed by Inker et al) uses serum cystatin C, age, and sex to estimate eGFR and is the most widely validated cystatin C-based formula. The combined CKD-EPI Creatinine-Cystatin C equation (2012, updated in 2021) incorporates both biomarkers and is the most accurate single GFR estimating equation available — better than either biomarker alone — because it reduces the impact of non-GFR determinants of each marker. Cystatin C-based eGFR is particularly valuable in staging CKD when creatinine gives borderline results around GFR 60, in liver disease (where creatinine production may be reduced), and in confirming or refuting suspected CKD in patients with low muscle mass. The KDIGO 2024 CKD guidelines recommend using the combined equation when creatinine alone gives an eGFR of 45-90 mL/min/1.73m² and the CKD diagnosis is uncertain.
2012 CKD-EPI Cystatin C: eGFR = 133 × min(CysC/0.8, 1)^(-0.499) × max(CysC/0.8, 1)^(-1.328) × 0.996^Age × 0.932 (if female); Combined CKD-EPI CysC+Cr (2012): uses both creatinine and cystatin C with sex-specific constants
- 1Measure serum cystatin C using a standardised, IFCC-traceable immunoassay (nephelometry or turbidimetry); ensure the laboratory uses IFCC-standardised reagents as non-standardised assays give different numeric results
- 2Identify patient age in years and biological sex (male or female) — two variables used in the CKD-EPI Cystatin C equation alongside CysC
- 3Apply the 2012 CKD-EPI Cystatin C equation: calculate min(CysC/0.8, 1) — this is CysC/0.8 if below 1.0, or 1.0 if CysC/0.8 exceeds 1.0; calculate max(CysC/0.8, 1) — the complementary value
- 4Raise the min term to the power of -0.499 and the max term to the power of -1.328; multiply by 133, then by 0.996 raised to the power of the patient's age, and by the sex coefficient (0.932 for female, 1.000 for male)
- 5If both serum creatinine and cystatin C are available, use the combined CKD-EPI Creatinine-Cystatin C equation for higher accuracy — it uses both biomarkers simultaneously with their respective sex-specific scaling constants
- 6Stage the resulting eGFR using KDIGO CKD classification (G1 through G5) and interpret in context of albuminuria, clinical history, and GFR trajectory
- 7Consider cystatin C to confirm or reclassify CKD staging when creatinine-based eGFR is in the borderline range (45-90 mL/min/1.73m²) — this is the clinical scenario where cystatin C adds most diagnostic value
True GFR ~50, not 95 — creatinine over-estimated GFR by nearly 50%
In sarcopenic elderly patients, low muscle mass produces less creatinine, making serum creatinine appear falsely low and creatinine-based eGFR falsely high. Cystatin C, unaffected by muscle mass, reveals the true degree of kidney function impairment.
Reduced limb mass causes creatinine eGFR to substantially overestimate true GFR
Amputation reduces total muscle mass and therefore creatinine generation. CysC-based eGFR (80) more accurately reflects kidney function. Drug dosing decisions, CKD staging, and monitoring should be based on the cystatin C result in this patient.
Agreement between equations confirms the eGFR estimate is reliable
When creatinine eGFR is in the borderline 45-90 range, cystatin C confirmation is recommended by KDIGO 2024. Concordant results give greater confidence in the staging. Persistent eGFR < 60 for > 3 months confirms CKD diagnosis.
Hypothyroidism raises cystatin C non-GFR dependently — CysC unreliable in thyroid disease
Thyroid hormones regulate cystatin C gene transcription. Hypothyroidism increases cystatin C production, causing overestimation of CKD severity. Hyperthyroidism decreases cystatin C, causing underestimation. Always check thyroid function before interpreting CysC-based eGFR.
Detecting hidden kidney impairment in sarcopenic elderly patients where creatinine-based eGFR falsely suggests normal function, preventing inadvertent overdosing of renally cleared drugs. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Confirming or refuting CKD staging in borderline cases (eGFR 45-90 mL/min/1.73m²) to avoid inappropriate labelling of normal individuals as having CKD or missing true CKD. Industry practitioners rely on this calculation to benchmark performance, compare alternatives, and ensure compliance with established standards and regulatory requirements
Accurately staging CKD in amputees, patients with neuromuscular disease, and those with extreme body composition — populations where creatinine is inherently unreliable. Academic researchers and students use this computation to validate theoretical models, complete coursework assignments, and develop deeper understanding of the underlying mathematical principles
Guiding drug dose adjustment for renally cleared medications (anticoagulants, antibiotics, chemotherapy) in patients with atypical muscle mass where creatinine gives misleading guidance. Financial analysts and planners incorporate this calculation into their workflow to produce accurate forecasts, evaluate risk scenarios, and present data-driven recommendations to stakeholders
Providing a race-free, muscle-independent GFR estimate that addresses known equity concerns with creatinine-based equations in populations with variable muscle mass by race or ethnicity. This application is commonly used by professionals who need precise quantitative analysis to support decision-making, budgeting, and strategic planning in their respective fields
Liver Cirrhosis
In liver cirrhosis, both creatinine and cystatin C can be problematic GFR markers. Creatinine is falsely low due to reduced hepatic creatinine synthesis and reduced muscle mass. Cystatin C may be affected by altered protein metabolism, oedema, and reduced lymphatic drainage in cirrhosis. For patients with cirrhosis, measured GFR (using iohexol or iothalamate clearance) or creatinine clearance by 24-hour urine collection may be more reliable than any estimated equation. The MELD score uses creatinine but acknowledges its limitations in this population.
Kidney Transplant Recipients
In kidney transplant recipients, cystatin C-based eGFR may be less accurate because corticosteroids (a standard part of immunosuppression) increase cystatin C production independent of GFR. This causes cystatin C to overestimate the degree of dysfunction. Measured GFR remains the gold standard for transplant follow-up. The combined equation may partially mitigate this limitation.
Critical Illness and AKI
In the ICU setting with acute kidney injury, both creatinine and cystatin C are unreliable eGFR markers. Creatinine generation may be reduced due to muscle catabolism or wasting, while cystatin C is affected by the systemic inflammatory response, corticosteroid use, and volume shifts. Neither should be used to estimate GFR in acute settings — GFR estimation equations are validated only for stable chronic kidney function.
Discordant Creatinine and Cystatin C eGFR
When the cystatin C eGFR is substantially lower than the creatinine eGFR (by more than 15-20 mL/min/1.73m²), this 'discordance' often reflects creatinine overestimating GFR due to low muscle mass, and cystatin C providing the more accurate estimate. However, if both are discordant without an obvious explanation, measured GFR should be considered. Discordance in the other direction (CysC much higher than Cr eGFR) may indicate cystatin C elevation from corticosteroids, thyroid disease, or inflammation.
Children and Paediatric Use
The CKD-EPI Cystatin C equations are validated in adults (aged 18 and over). In children, the Schwartz cystatin C equation is preferred. In adolescents aged 14-18, either adult or paediatric equations may be used with caution. Cystatin C is particularly useful in children because muscle mass varies substantially with age and growth, making creatinine-based estimations less reliable.
| Feature | Serum Creatinine | Serum Cystatin C |
|---|---|---|
| Production source | Muscle (creatine metabolism) | All nucleated cells (constant) |
| Effect of muscle mass | High — proportional to muscle | Minimal — independent |
| Effect of diet | High-protein raises creatinine | No significant dietary effect |
| Effect of age/sex | Significant — muscle changes | Minor — small age effect |
| Effect of thyroid status | Minimal | Significant — hypothyroidism raises CysC |
| Effect of corticosteroids | Minimal | Raises CysC production |
| Tubular handling | Some secretion by tubules | Full reabsorption and catabolism |
| Cost | Very low | 3-5 times creatinine cost |
| Accuracy in low muscle mass | Poor (overestimates GFR) | Good |
| Race-free equation available | Yes (CKD-EPI 2021) | Yes (CKD-EPI CysC 2012) |
Why is cystatin C considered better than creatinine for estimating GFR?
Creatinine production is proportional to muscle mass, which varies widely by age, sex, race, body composition, diet, and physical activity. Cystatin C is produced at a constant rate by all nucleated cells regardless of muscle mass or diet. This makes cystatin C a more reliable marker in populations with atypical muscle mass — elderly, sarcopenic, obese, amputees, malnutrition, bodybuilders, vegan athletes — where creatinine-based eGFR can be significantly misleading.
What factors raise cystatin C without changing GFR?
Hypothyroidism significantly increases cystatin C production (thyroid hormones suppress cystatin C gene transcription). High-dose corticosteroids increase cystatin C production. Smoking has been associated with mildly elevated cystatin C. Malignancy and inflammation may also affect levels. These non-GFR determinants of cystatin C are important when interpreting results, particularly in patients on corticosteroids or with untreated thyroid disease.
When should cystatin C be ordered instead of or in addition to creatinine?
KDIGO 2024 recommends cystatin C (ideally the combined equation) when: (1) creatinine-based eGFR is in the borderline range 45-90 mL/min/1.73m² and CKD diagnosis is uncertain; (2) the patient has atypical muscle mass (elderly, amputee, paralysis, malnutrition, obesity, bodybuilder); (3) confirming CKD staging for clinical decisions about referral, drug dosing, or transplant listing; (4) liver disease where creatinine production may be reduced.
How accurate is the combined CKD-EPI CysC + Creatinine equation?
The combined 2012 CKD-EPI Creatinine-Cystatin C equation has a P30 accuracy (percentage of estimates within 30% of measured GFR) of approximately 91-93%, compared to approximately 86-90% for creatinine-only equations and 88-91% for cystatin C-only equations. By incorporating both markers, the combined equation reduces the impact of non-GFR determinants of either individual biomarker, making it the most accurate clinical eGFR equation currently available.
Is cystatin C affected by race or ethnicity?
Unlike creatinine-based equations (which historically included race coefficients since removed from CKD-EPI 2021), cystatin C-based equations do not include race-specific adjustments. Studies suggest cystatin C is more equitable across racial and ethnic groups, which contributed to KDIGO's recommendation of cystatin C confirmation as an alternative to race-based creatinine adjustments. This is an important consideration when working with cystatin c gfr calculations in practical applications.
What are the disadvantages of cystatin C testing?
Cystatin C is more expensive than creatinine (approximately 3-5 times the cost in most health systems) and is not universally available. Assay standardisation (IFCC traceable calibration) is important — laboratories using non-standardised assays produce results that cannot be directly inserted into published equations validated with standardised assays. Additionally, non-GFR factors (thyroid dysfunction, corticosteroids, inflammation) affect levels, requiring clinical context.
Does cystatin C help with drug dosing decisions?
Yes. For drugs with narrow therapeutic windows and significant renal clearance — such as direct oral anticoagulants (DOACs), aminoglycosides, methotrexate, and chemotherapy agents — more accurate GFR estimation is clinically important. In patients where creatinine-based eGFR is likely misleading (e.g., elderly, low muscle mass), cystatin C-based eGFR provides better guidance for dosing decisions. Some pharmacokinetic studies now use measured GFR or cystatin C-based estimates for drug dose calculation.
How does cystatin C-based eGFR relate to cardiovascular risk?
Multiple large cohort studies (CKD-EPI, ARIC, Cardiovascular Health Study) have shown that cystatin C-based eGFR is at least as strongly associated with cardiovascular mortality and all-cause mortality as creatinine-based eGFR, and in some analyses is a superior predictor in older adults. Discordantly low cystatin C eGFR compared to creatinine eGFR (suggesting creatinine overestimates GFR) is associated with higher cardiovascular risk independent of creatinine-based staging.
Pro Tip
When creatinine-based eGFR is 45-90 mL/min/1.73m² and the clinical picture is uncertain, ordering cystatin C and using the combined equation can clarify whether the patient truly has CKD. Concordant results from both biomarkers significantly increase confidence in the GFR estimate.
Did you know?
Cystatin C was identified as a potential GFR marker as early as 1985 by Simonsen et al, but it took nearly 20 years for standardised assays and validated equations (CKD-EPI 2012) to make it a practical clinical tool. The protein's name comes from its classification as a cysteine protease inhibitor — its biological role is to regulate cysteine proteases involved in intracellular protein degradation.
References
- ›Inker LA et al — Estimating GFR Using Serum Creatinine and Cystatin C (CKD-EPI 2012, NEJM)
- ›KDIGO 2024 CKD Clinical Practice Guideline
- ›Dharnidharka VR et al — Serum Cystatin C is Superior to Serum Creatinine as a Marker of Kidney Function (meta-analysis)
- ›Shlipak MG et al — Cystatin C versus Creatinine in Determining Risk Based on Kidney Function (NEJM 2013)
- ›NKF-ASN Task Force 2021 — Reassessing the Inclusion of Race in Diagnosing Kidney Disease